Akeso Biopharma

Asia
Pharma

Akeso-Summit, BIOSECURE, Candid and more—Fierce Pharma Asia

Akeso and Summit's ivonescimab handily beat Keytruda in a China phase 3 study. The House passed the BIOSECURE Act. Candid emerged with $370 million.
Angus Liu Sep 13, 2024 8:53am
boxing punch blow hit punching bag fight

Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study

Sep 8, 2024 11:30am
ASCO

Daiichi, Akeso, Genscript and Legend— Fierce Pharma Asia

Jun 7, 2024 6:00am
head-to-head faceoff competition

Summit and Akeso deliver Keytruda-topping results in NSCLC

May 31, 2024 11:00am
Asia

AstraZeneca, Takeda, BioNTech—Fierce Pharma Asia

Nov 10, 2023 8:05am
BMS flag

Novartis, BMS, Innovent, Lilly, Akebia await FDA decisions

Mar 2, 2022 10:10am